✦ LIBER ✦

Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study

✍ Scribed by Paul D Miller; Michael R Mcclung; Liviu Macovei; Jacob A Stakkestad; Marjorie Luckey; Bernard Bonvoisin; Jean-Yves Reginster; Robert R Recker; Claire Hughes; E Michael Lewiecki; Dieter Felsenberg; Pierre D Delmas; David L Kendler; Michael A Bolognese; Nicole Mairon; Cyrus Cooper

Book ID: 111485273
Publisher: American Society for Bone and Mineral Research
Year: 2005
Tongue: English
Weight: 128 KB
Volume: 20
Category: Article
ISSN: 0884-0431
DOI: 10.1359/jbmr.050313

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and tolerability of once-monthl

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

✍ Ronald Emkey; Pierre D. Delmas; Michael Bolognese; Joao Lindolfo C. Borges; Feli 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Intravenous ibandronate injections in po

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

✍ Pierre D. Delmas; Silvano Adami; Cezary Strugala; Jacob A. Stakkestad; Jean-Yves 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB

## Abstract ## Objective Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patients. Ibandronate, a potent nitroge

Histomorphometric evaluation of daily an

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study

✍ R.R. Recker; R.S. Weinstein; C.H. Chesnut; R.C. Schimmer; P. Mahoney; C. Hughes; 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 205 KB

Oral ibandronate reduces non-vertebral f

Oral ibandronate reduces non-vertebral fracture risk in postmenopausal osteoporosis: Results from a sub-analysis of a pivotal study

✍ Jacob A. Stakkestad; Ronald Emkey; Colin Neate; Charles H. Chesnut 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

OC5. Prevention of anastrozole induced b

OC5. Prevention of anastrozole induced bone loss with monthly oral ibandronate during adjuvant breast cancer therapy: Two year results from the ARIBON study

✍ James Lester; David Dodwell; Omprakash Purohit; Sandra Gutcher; Sue Ellis; Ruth 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 39 KB

Oral ibandronate significantly reduces t

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis

✍ D. Felsenberg; P. Miller; G. Armbrecht; K. Wilson; R.C. Schimmer; S.E. Papapoulo 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 120 KB